CRSP
Crispr Therapeutics AG
NASDAQ: CRSP · HEALTHCARE · BIOTECHNOLOGY
$50.71
-2.59% today
Updated 2026-04-29
Market cap
$4.70B
P/E ratio
—
P/S ratio
1,340.31x
EPS (TTM)
$-6.47
Dividend yield
—
52W range
$33 – $78
Volume
2.0M
Crispr Therapeutics AG (CRSP) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.53M | $159.42M | $344.96M | $271.35M | $489.02M | $1.07B | $1.83B | $2.75B | $2.24B | $2.23B | $2.24B |
| Cash & equivalents | — | — | — | — | — | — | — | — | — | — | — |
| Current assets | $968000.00 | $156.84M | $320.19M | $248.38M | $466.39M | $987.55M | $1.72B | $2.42B | $1.85B | $1.91B | $1.94B |
| Total liabilities | $8.50M | $188.55M | $112.12M | $83.51M | $96.82M | $127.33M | $163.73M | $352.42M | $367.58M | $346.77M | $309.95M |
| Current liabilities | $2.15M | $10.15M | $22.00M | $14.51M | $27.75M | $57.11M | $94.26M | $119.88M | $121.11M | $108.79M | $87.78M |
| Long-term debt | $38.00M | $38.34M | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Shareholder equity | — | — | — | — | — | — | — | — | — | — | — |
| Retained earnings | $-8.40M | $-33.91M | $-57.08M | $-125.44M | $-291.57M | $-224.71M | $-573.58M | $-195.91M | $-846.09M | $-999.70M | $-1.37B |
| Accounts receivable | $3.00M | $339000.00 | $3.16M | $2.63M | $88000.00 | $99000.00 | $10.84M | $305000.00 | $11.20M | $200.00M | $25.00M |
| Inventory | — | $1.00 | $0.00 | $1.00 | $1.00 | $1.00 | — | — | $-11.20M | — | — |
| Goodwill | — | — | $0.00 | $0.00 | — | — | — | — | — | — | — |